Dr. Nepom received his bachelor’s degree in Biochemistry from Harvard in 1972 and doctorates from the University of Washington, receiving his PhD in Biochemistry in 1977 and his MD in 1978. After post-doctoral work in immunogenetics in the Department of Pathology at Harvard Medical School, he returned to Seattle, joining the Fred Hutchinson Cancer Research Center and the University of Washington Medical School Faculty in 1982. Since 1985 he has been a Member of the Benaroya Research Institute at Virginia Mason (BRI) and served as Director of BRI from 1985 through 2015. Dr. Nepom also served as Director of the Immune Tolerance Network (ITN), sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) from 2010 to 2022. He is currently an Emeritus Faculty Member of BRI and Senior Advisor to ITN.
Area Of Research
Dr. Nepom's interests are focused on identifying and understanding molecular and genetic mechanisms contributing to pathogenesis of autoimmune disorders and using this information to evaluate autoreactive T cell lineage and fate determination. Translational and clinical applications include development and use of immunological monitoring tools for predicting disease susceptibility and response to therapy in clinical trials, with special emphasis on type 1 diabetes.
One Step Closer to Preventing Celiac Disease
Celiac disease, like all autoimmune diseases, has no cure. People with the condition must adhere to a strict gluten-free diet or face symptoms like nausea, vomiting, ulcers and intestinal damage.
Improving Diabetes Research Worldwide
Type 1 diabetes (T1D) is an immensely complex disease, which means it’s going to take many minds—and many approaches—to conquer it. BRI plays a key role in this fight. Here are three ways we're using our expertise to improve research worldwide.
Landmark Studies Shows Strides Against Peanut Allergies
A landmark study called LEAP (Learning Early About Peanut Allergy) demonstrated that regular peanut consumption begun in early infancy and continued until age five reduced the rate of peanut allergy in at-risk infants by 80 percent compared to non-peanut consumers.